EC Number   |
Expression |
Reference |
|---|
   3.4.24.24 | down |
inhibition of the SDF-1a/CXCR4 axis downregulates the rhOPN-induced MMP-2 expression and activity |
718288 |
| 3.4.24.24 | down |
matrix metalloproteinase 2 activity decreases in human periodontal ligament fibroblast cultures submitted to simulated orthodontic force by centrifugation (141xg) for 30, 60, 90, and 120 min at 24 h regardless of the duration of centrifugation and at 48 h in cells centrifuged for 30 min only |
712141 |
| 3.4.24.24 | down |
peptide Ile-Trp isoleucine-tryptophan inhibits expression and activity of matrix metalloproteinase-2 in rat aorta, mechanism of action, overview. The inhibitor significantly inhibits ANGI, but not ANGII mediated increase in expression of MMP2, while losartan also blocks effects of ANGII. Signaling pathways regulating MMP2 expression in endothelial cells and smooth muscle cells are similarly inhibited after treatment with Ile-Trp or captopril. Ile-Trp not only inhibits the MMP2 expression, but also its activation assessed with gelatin zymography |
754999 |
| 3.4.24.24 | down |
profibrogenic gene expression of MMP-2 is down-regulated (75% decrement) in response to adenoviral delivery of dominant-negative transforming growth factor beta type II receptor in hepatic stellate cells |
712625 |
| 3.4.24.24 | more |
promoter activity of LvMMP-2 is enhanced by LvNRF2 in a ARE site dependent-manner. Overexpression of Lvc-Jun in S2 cells demonstrates that AP-1 is also involved in LvMMP-2 regulation |
753613 |
| 3.4.24.24 | up |
expression and activity of MMP-2 is 6fold induced by osteopontin through binding to integrin avb3 and CD44v6 in hepatocellular carcinoma cells SMMC7721 and HepG2 |
718288 |
| 3.4.24.24 | up |
in vitro, both angiotensin II (ANGII) and ANGI stimulation significantly increase expression of MMP2 |
754999 |
| 3.4.24.24 | up |
Mycobacterium tuberculosis stimulates matrix metalloproteinases secretion in the host |
754641 |
| 3.4.24.24 | up |
oxidative stress increases the expression of LvMMP-2 |
753613 |
| 3.4.24.24 | up |
significant progressive increase in total MMP-2 plasma levels with progression from adenomatous polyps through advancing Dukes stages |
752558 |
